Skip to main content
. 2023 Feb 9;128(8):1503–1513. doi: 10.1038/s41416-022-02108-7

Fig. 2. Subsequent treatments.

Fig. 2

ST subsequent treatment, VEGFi vascular endothelial growth factor inhibitor, PARPi poly ADP-ribose polymerase inhibitors, PLD pegylated liposomial doxorubicin.